Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 5:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 386 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Transplant Symptoms Clear all
Completed Phase 4 Interventional Results available

Pharmacokinetics of Sublingual Versus Oral Tacrolimus in Patients Awaiting Kidney Transplantation

NCT00629122
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Tacrolimus (Arm B), Clotrimazole Troche, Tacrolimus (Arm A), Nystatin Suspension
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 7, 2026, 5:52 AM EDT
Not yet recruiting Not applicable Interventional

Development and Test of a Communication Skills Training for Transplant Providers - Aims 2 & 3

NCT06182475
View directory record Official record
Conditions
Kidney Disease, Chronic, End Stage Renal Disease, Kidney Replacement
Interventions
EPPComm Provider Training
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Livingston, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 7, 2026, 5:52 AM EDT
Terminated Not applicable Interventional Results available

Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline

NCT02123576
View directory record Official record
Conditions
Hepatorenal Syndrome
Interventions
Pentoxyfylline, Placebo, AMO Therapy
Drug
Lead sponsor
Patrick Northup, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 7, 2026, 5:52 AM EDT
Completed Phase 2 Interventional Results available

Ixazomib for Desensitization

NCT03213158
View directory record Official record
Conditions
Kidney Diseases, End Stage Renal Disease
Interventions
Ixazomib Oral Capsule
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 7, 2026, 5:52 AM EDT
Completed Not applicable Interventional

Does an Abdominal Wall Nerve Block During Surgery Help Reduce Pain From Kidney Transplantation?

NCT05280197
View directory record Official record
Conditions
Kidney Transplantation
Interventions
TAP block, liposomal bupivacaine plus free bupivacaine, normal saline
Procedure · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 7, 2026, 5:52 AM EDT
Completed Phase 4 Interventional Results available

Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients

NCT02781649
View directory record Official record
Conditions
End-Stage Renal Disease, Hepatitis C
Interventions
Zepatier, Ribavirin, Sofosbuvir
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 7, 2026, 5:52 AM EDT
Recruiting Not applicable Interventional

CAPABLE Transplant

NCT06326905
View directory record Official record
Conditions
Quality of Life, Depression, End Stage Renal Disease, Disability Physical
Interventions
CAPABLE Transplant- Open Label Pilot, CAPABLE Transplant- Randomized Control Trial
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 7, 2026, 5:52 AM EDT
Completed Phase 1Phase 2 Interventional

Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon

NCT00010283
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
beclomethasone dipropionate
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
5 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 7, 2026, 5:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Implementation of the Live Donor Champion Program

NCT03435510
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
Live Donor Champion Program
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
2
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 7, 2026, 5:52 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD

NCT06878560
View directory record Official record
Conditions
ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation
Interventions
10 GE Xenokidney
Biological
Lead sponsor
United Therapeutics
Industry
Eligibility
40 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2075
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 7, 2026, 5:52 AM EDT
Recruiting Not applicable Interventional

Prehabilitation for Kidney Transplant Candidates

NCT06886256
View directory record Official record
Conditions
Kidney Transplantation, Frailty, Chronic Kidney Insufficiency
Interventions
Polar H10 Heart Rate Monitor, Empatica EmbracePlus, Apple Watch Ultra 2
Device
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
55 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 7, 2026, 5:52 AM EDT
Completed No phase listed Observational

Comparison of Markers of Kidney Function

NCT01403766
View directory record Official record
Conditions
Chronic Kidney Disease, Renal Insufficiency
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
1 Year to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 7, 2026, 5:52 AM EDT
Terminated Phase 4 Interventional Results available

Postoperative Pain Control Following Renal Transplant

NCT05044429
View directory record Official record
Conditions
Kidney Transplant; Complications, Pain, Postoperative
Interventions
Intravenous Lidocaine, Transversus abdominis plane (TAP) block, Quadratus Lumborum (QL) Block
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 7, 2026, 5:52 AM EDT
Recruiting Phase 3 Interventional

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

NCT06830798
View directory record Official record
Conditions
Delayed Graft Function, DGF, Kidney Transplant
Interventions
Ravulizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
32
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 7, 2026, 5:52 AM EDT
Completed Not applicable Interventional

Comparison of AVF Versus AVG in Elderly Patients Starting Dialysis

NCT02981706
View directory record Official record
Conditions
Chronic Kidney Disease, Endstage Renal Disease
Interventions
Arteriovenous Fistula (AVF), Arteriovenous Graft (AVG)
Procedure
Lead sponsor
Columbia University
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Oct 7, 2026, 5:52 AM EDT
Active, not recruiting Not applicable Interventional

The Arteriovenous Vascular (AV) ACCESS Trial

NCT04646226
View directory record Official record
Conditions
End-Stage Kidney Disease, Hemodialysis Complication
Interventions
AV graft, surgical intervention for creation of a fistula
Device · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • Los Angeles, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 7, 2026, 5:52 AM EDT
Terminated Phase 2 Interventional

Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%

NCT00090194
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Immune Globulin Intravenous (Human), 10%
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 7, 2026, 5:52 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Intravenous Estrogen in Kidney Transplant Study

NCT03663543
View directory record Official record
Conditions
Ischemia Reperfusion Injury
Interventions
Conjugated Estrogen, Normal saline
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 7, 2026, 5:52 AM EDT
Completed No phase listed Observational

Live Kidney Donor Study

NCT00608283
View directory record Official record
Conditions
Kidney Transplantation, End Stage Renal Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
8,951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 7, 2026, 5:52 AM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 7, 2026, 5:52 AM EDT
Completed No phase listed Observational

Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus

NCT03413722
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Tacrolimus, Everolimus
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 7, 2026, 5:52 AM EDT
Withdrawn Phase 4 Interventional

Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access

NCT04614142
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Hepatitis c
Interventions
Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
34 Years to 44 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 7, 2026, 5:52 AM EDT
Enrolling by invitation No phase listed Observational

System Interventions to Achieve Early and Equitable Transplants Study - Long-Term

NCT07515794
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 7, 2026, 5:52 AM EDT
Terminated Phase 4 Interventional Results available

Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation

NCT00936663
View directory record Official record
Conditions
Type 2 Diabetes, End Stage Renal Disease
Interventions
Placebo, Sitagliptin
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 7, 2026, 5:52 AM EDT